Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David Marin

Showing results (91-100 of 180) with videos related to

Pageof 18
Sort By:
Blood|September 22, 2010
EVI-1 oncogene expression predicts survival in chronic-phase CML patients resistant to imatinib treated with second-generation tyrosine kinase inhibitorsMustafa Daghistani, David Marin, Jamshid Sorouri Khorashad, et al.
Frontiers in Immunology|January 30, 2018
Evidence for B Cell Exhaustion in Chronic Graft-versus-Host DiseaseAhmad Khoder, Abdullah Alsuliman, Rafet Basar, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 10, 2011
Assessment of BCR-ABL1 transcript levels at 3 months is the only requirement for predicting outcome for patients with chronic myeloid leukemia treated with tyrosine kinase inhibitorsDavid Marin, Amr R Ibrahim, Claire Lucas, et al.
Blood|June 22, 2010
Interaction between KIR3DS1 and HLA-Bw4 predicts for progression-free survival after autologous stem cell transplantation in patients with multiple myelomaIan H Gabriel, Ruhena Sergeant, Richard Szydlo, et al.
Haematologica|October 17, 2009
Early prediction of success or failure of treatment with second-generation tyrosine kinase inhibitors in patients with chronic myeloid leukemiaDragana Milojkovic, Emma Nicholson, Jane F Apperley, et al.
Bone Marrow Transplantation|September 19, 2023
Hematopoietic cell transplantation can be safely performed after COVID-19Alejandro Marinos, Jeremy Ramdial, Fareed Khawaja, et al.
Haematologica|August 20, 2016
Pre-transplantation minimal residual disease with cytogenetic and molecular diagnostic features improves risk stratification in acute myeloid leukemiaBetül Oran, Jeff L Jorgensen, David Marin, et al.
Transplantation and Cellular Therapy|December 2, 2023
Ex Vivo Expanded Cord Blood Natural Killer Cells Combined with Rituximab and High-Dose Chemotherapy and Autologous Stem Cell Transplantation for B Cell Non-Hodgkin LymphomaYago Nieto, Pinaki Banerjee, Indresh Kaur, et al.
Blood|February 25, 2011
Poor adherence is the main reason for loss of CCyR and imatinib failure for chronic myeloid leukemia patients on long-term therapyAmr R Ibrahim, Lina Eliasson, Jane F Apperley, et al.
Blood|July 24, 2012
Dasatinib may overcome the negative prognostic impact of KIR2DS1 in newly diagnosed patients with chronic myeloid leukemiaSara Ali, Ruhena Sergeant, Stephen G O'Brien, et al.
Pageof 18

Showing results (91-100 of 180) with videos related to

Sort By:
Pageof 18
Blood|September 22, 2010
EVI-1 oncogene expression predicts survival in chronic-phase CML patients resistant to imatinib treated with second-generation tyrosine kinase inhibitorsMustafa Daghistani, David Marin, Jamshid Sorouri Khorashad, et al.
Frontiers in Immunology|January 30, 2018
Evidence for B Cell Exhaustion in Chronic Graft-versus-Host DiseaseAhmad Khoder, Abdullah Alsuliman, Rafet Basar, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 10, 2011
Assessment of BCR-ABL1 transcript levels at 3 months is the only requirement for predicting outcome for patients with chronic myeloid leukemia treated with tyrosine kinase inhibitorsDavid Marin, Amr R Ibrahim, Claire Lucas, et al.
Blood|June 22, 2010
Interaction between KIR3DS1 and HLA-Bw4 predicts for progression-free survival after autologous stem cell transplantation in patients with multiple myelomaIan H Gabriel, Ruhena Sergeant, Richard Szydlo, et al.
Haematologica|October 17, 2009
Early prediction of success or failure of treatment with second-generation tyrosine kinase inhibitors in patients with chronic myeloid leukemiaDragana Milojkovic, Emma Nicholson, Jane F Apperley, et al.
Bone Marrow Transplantation|September 19, 2023
Hematopoietic cell transplantation can be safely performed after COVID-19Alejandro Marinos, Jeremy Ramdial, Fareed Khawaja, et al.
Haematologica|August 20, 2016
Pre-transplantation minimal residual disease with cytogenetic and molecular diagnostic features improves risk stratification in acute myeloid leukemiaBetül Oran, Jeff L Jorgensen, David Marin, et al.
Transplantation and Cellular Therapy|December 2, 2023
Ex Vivo Expanded Cord Blood Natural Killer Cells Combined with Rituximab and High-Dose Chemotherapy and Autologous Stem Cell Transplantation for B Cell Non-Hodgkin LymphomaYago Nieto, Pinaki Banerjee, Indresh Kaur, et al.
Blood|February 25, 2011
Poor adherence is the main reason for loss of CCyR and imatinib failure for chronic myeloid leukemia patients on long-term therapyAmr R Ibrahim, Lina Eliasson, Jane F Apperley, et al.
Blood|July 24, 2012
Dasatinib may overcome the negative prognostic impact of KIR2DS1 in newly diagnosed patients with chronic myeloid leukemiaSara Ali, Ruhena Sergeant, Stephen G O'Brien, et al.
Pageof 18